The Era Of Big Pharma Fraud Cases Is Ending, Former U.S. Attorney Loucks Says - But It May End With A Bang
Executive Summary
The wave of massive health care fraud settlements involving biopharmaceutical companies appears to be drawing to a close - but pressure for more draconian penalties means it may end with a bang
You may also be interested in...
Rx Fraud Investigations Could Get Boost From Health Care Reform's Transparency Requirements
Former DoJ prosecutor Michael Loucks says there is pressure from Congress to exclude companies from government programs, particularly if they have prior settlements with the government.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011